CDKN2D and neoplasm: Lastly, CDKN2D-WDFY2 could be used as a clinical biomarker for detection of a substantial fraction of HG-SC, as this specific molecular signature might be present in circulating cancer cells or in local body fluids released from tumor mass thus detectable using non-invasive assays.